Physician profile
Morgan Carter
NPI 1972127173
$4,969.44
in general payments reported to CMS, 2019-2025
44 companies · $854 in 2025
The $854 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $882 · 2022: $1,350 · 2023: $913 · 2024: $970 · 2025: $854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,737.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,737.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $726.34 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $488.06 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $468.77 | 2021-2025 | Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $440.61 | 2022-2025 | |
| Pfizer INC. | $358.83 | 2021-2025 | |
| Novo Nordisk INC | $261.91 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $260.85 | 2021-2023 | |
| Amgen INC. | $259.78 | 2021-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $192.67 | 2021-2023 | Jardiance |
| Indivior INC. | $177.29 | 2024-2025 | Sublocade |
| Novartis Pharmaceuticals Corporation | $144.77 | 2021-2025 | |
| Corcept Therapeutics | $136.20 | 2023-2024 | Korlym |
| Calliditas Therapeutics US INC. | $119.63 | 2023-2025 | Tarpeyo |
| Daiichi Sankyo INC. | $100.54 | 2022-2025 | Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $54.62 | 2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.